- PanOptix, the first and only advanced trifocal lens for U.S.
patients undergoing cataract surgery, will be showcased in
educational events and clinical data presentations
- First-ever analyses on IOLs from the AAO IRIS Registry – the
largest real-world dataset in ophthalmology – will be presented,
supporting the clinical value of the AcrySof platform
- Additional educational opportunities will take place at the
Alcon booth (#539) including Surgeon2Surgeon presentations and
virtual reality learning modul
Alcon, the global leader in eye care dedicated to helping people
see brilliantly, today announced its plans to lead a wide-range of
informational and peer-to-peer educational programs at the American
Academy of Ophthalmology (AAO) Annual Meeting on October 12-15 in
San Francisco, CA. The newly launched AcrySof® IQ PanOptix®
Trifocal Intraocular Lens (IOL), along with findings from the AAO
IRIS® (Intelligent Research in Sight) Registry, will be part of the
scientific program.
“We are thrilled to showcase PanOptix, the first and only
advanced trifocal IOL approved in the U.S., at the meeting,
underscoring our continued commitment to innovation,” said Sergio
Duplan, Region President, North America. “However, our focus goes
beyond just bringing new products to the market. We are also
dedicated to ongoing learning about our current portfolio as shown
with the AAO IRIS Registry, which has allowed us to use an
unprecedented amount of real-world data to help validate the
performance of our AcrySof platform.”
Showcasing PanOptix, the First and Only FDA-approved Advanced
Trifocal IOL
PanOptix, which received FDA-approval in August, is the first
and only advanced trifocal lens approved in the US. 20/20 near,
intermediate and distance vision is now possible with this new
lens.1 PanOptix is already one of the leading presbyopia-correcting
IOLs, with over 400,000 implants in more than 70 countries. Based
on years of experience with the lens, Alcon plans to share best
practices and hands-on training, including virtual reality kiosks
at the Alcon booth where surgeons can learn first-hand about
PanOptix and how it works. Additional highlights will include:
Clinical Presentation
- E-Poster: Evaluation of the Binocular Depth of Focus of a New
Trifocal IOL, R. P. Lehmann
Peer-to-Peer Learning
- Feel the Thrill PanOptix launch event where surgeons hear from
other surgeons in an interactive format (Saturday, October 12 at
5:30 PM Terra Gallery, 511 Harrison Street)
- Surgeon2Surgeon Talks where clinical trial investigators will
share their first-hand clinical experience with the new lens (Alcon
Booth, #539)
Investigating the Real-World Performance of IOLs
Alcon has supported prospective real-world evidence studies to
better understand outcomes of its products. The studies used the
American Academy of Ophthalmology IRIS Registry, the largest
clinical specialty database in the world, and were completed in
collaboration with Verana Health, the Academy’s data curation and
analytics partner. As of September 1, 2019, the IRIS Registry
included approximately 253 million patient visits, representing
more than 61 million unique patients.
Clinical Presentations
- Paper Presentation, Tuesday, October 15, 11:03 AM – 11:10 AM:
Incidence of Monofocal Toric IOL Repositioning: Analysis of the AAO
IRIS Registry; B.A. Kramer, J.P. Berdahl
- Paper Presentation, Tuesday, October 15, 11:27 AM – 11:34 AM:
The Potential Benefit of Lower-Powered Toric IOLs According to the
Astigmatism Fix Database; B.A. Kramer
- E-Poster: Incidence of YAG due to PCO Following IOL
Implantation: An Analysis of AAO IRIS Registry; J.D. Horn
- E-Poster: Description of Retrospective EHR-Based Registry Study
to Correlate Toric IOL Biomechanics with Repositioning Incidence;
B.A. Kramer
- E-Poster: Description of a Retrospective Study Using EHR-Based
Registry to Correlate IOL Biocompatibility with YAG; D.C.
Terveen
- E-Poster: Comparison of Time to PCO in Two Hydrophobic IOL
Materials: An Analysis of the AAO Clinical Registry; B.L.
Fisher
Providing Visualization Systems for Both Front and Back of
the Eye to US Surgeons
Alcon’s revolutionary NGENUITY® 3D Visualization System is now
available for both the anterior and posterior segments. Clinical
presentations about its real-world implementation in “heads-up”
cataract surgery will take place during AAO. The Alcon booth will
also feature other anterior segment visualization developments,
including LuxOR Revalia™ Ophthalmic Microscope, which delivers
enhanced visualization during all stages of ophthalmic surgery
through unique and personalized LED illumination technology.
In addition, the latest generation of the NGENUITY 3D
Visualization System with DATAFUSION for posterior segment surgery,
which was recently launched, will be highlighted at the 5th Annual
Retina Film Festival. This latest innovation includes a real-time
display of the CONSTELLATION® Vision System, the leading technology
platform for vitreoretinal surgery. It also allows surgeons to
control surgical parameters using the graphic user interface and
foot pedal.
Clinical Presentations
- Paper Presentation, Sunday, October 13, 4:18 PM - 4:25 PM:
Heads-Up Cataract Surgery: Complication Rates, Surgical Duration
and Comparison with Traditional Microscopes, R. J. Weinstock
- E-Poster: Heads-Up Cataract Surgery Using NGENUITY System, J.
Nemcansky
Peer-to-Peer Learning
- The 5th Annual Retina Exchange Film Festival, an engaging video-based program discussing the
latest in surgical retina techniques (Saturday, October 12, 2019 at
5:45 PM, Yerba Buena Center for the Arts)
- Surgeon2Surgeon Talks where surgeons will share their
first-hand clinical experience with NGENUITY (Alcon Booth,
#539)
All educational content at the AAO Annual Meeting is planned by
its program committee, and AAO does not endorse, promote, approve,
or recommend the use of any products, devices, or services.
About PanOptix
The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal
IOL used to focus images clearly onto the back of your eye (retina)
to allow clear vision after the cataract removal. In addition, the
center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better
near (reading) vision and intermediate (computer work) vision
versus what a monofocal lens would provide.
Due to the design of multifocal IOLs, there are some side
effects that can be associated with the AcrySof® IQ PanOptix®
Trifocal IOL models. These may be worse than with a monofocal IOL,
including visual disturbances such as glare, rings around lights,
starbursts (rays around light sources), and reduced contrast
sensitivity (decrease in ability to distinguish objects from their
background, especially in dim lighting). These side effects may
make it more difficult to see while driving at night or completing
tasks in low lighting conditions such as at night or in fog, or in
a dimly lit room after surgery as compared to before surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
About LuxOR Revalia™ Ophthalmic
Microscope
The LuxOR Revalia™ Ophthalmic Microscope features unique
technologies designed to optimize both anterior and posterior
procedures, providing superior visualization1 for every type of
ophthalmic surgery. As with all ophthalmic microscopes, exposure
during aphakia should be limited to reduce the risk of damage.
During aphakia, limit exposure to red reflex light to no more than
7 minutes.
About NGENUITY® 3D Visualization
System
The NGENUITY® 3D Visualization System consists of a 3D
stereoscopic, high-definition digital video camera and workstation
to provide magnified stereoscopic images of objects during
micro-surgery. It acts as an adjunct to the surgical microscope
during surgery displaying real-time images or images from
recordings. Please refer to the User Manual for a complete list of
appropriate uses, warnings and precautions.
Disclaimer
This announcement contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 that can generally be identified by words such as
“commitment,” “may,” “look forward,” “estimates,” “projected,”
“will,” “potential,” “anticipate,” “intend,” “plan,” “seek,”
“believe,” “expect,” “intention,” “should,” “maintaining” or
similar expressions, or by express or implied discussions regarding
the potential outcome, or financial or other impact on Alcon or any
of its businesses of the separation and spin-off from Novartis; or
regarding potential future sales or earnings of Alcon or any of its
businesses or potential shareholder returns; or by discussions of
strategy, plans, expectations or intentions. You should not place
undue reliance on these statements.
Such forward-looking statements are based on the current beliefs
and expectations of management regarding future events and are
subject to significant known and unknown risks and uncertainties.
There can be no guarantee that Alcon will be able to realize any of
the potential strategic benefits or opportunities as a result of
the separation and spin-off. Nor can there be any guarantee that
shareholders will achieve any particular level of shareholder
returns. Nor can there be any guarantee that Alcon, or any of its
businesses, be commercially successful in the future, or achieve
any particular credit rating or financial results. Nor can we
guarantee the separation and spin-off will be successful.
In particular, our expectations could be affected by, among
other things: uncertainties regarding the success of our separation
and spin-off from Novartis, including our ability to establish the
infrastructure needed to operate as a standalone company without
significant management distraction or business disruption; and
general political, economic and trade conditions, including
uncertainties regarding the effects of ongoing instability in
various parts of the world.
Some of these factors are discussed in more detail in Alcon’s
filings with the United States Securities and Exchange Commission,
including its Form 20-F, particularly under “Item 3. Key
Information—3.D. Risk Factors”, “Item 4. Information on the
Company” and “Item 5. Operating and Financial Review and
Prospects”. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated,
believed, estimated or expected. The statements in this
announcement are as of the date of its filing. We do not intend,
and do not assume any obligation, to update any information or
forward-looking statements set out in this announcement as a result
of new information, future events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Connect with us on
Facebook
LinkedIn
References
[1] AcrySof® IQ PanOptix® Directions For Use.
*Based on mean value of binocular defocus from curve at near,
intermediate and distance at 6 months. Snellen VA was converted
from logMAR VA. A Snellen notation of 20/20-2 or better indicates a
logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS
chart letters in the line were identified correctly.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191009005162/en/
Media Relations Blake Overby
+1 817 551 4328 (office) +1 682 321 2897
Blake-1.overby@alcon.com
Investor Relations Christina
Cheng + 1 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024